

CONTROL OF SUBSTANCES HAZARDOUS TO HEALTH (COSHH) SHEET

SECTION 1 – IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

PRODUCT NAME:

Docetaxel 20 mg/ ml concentrate for solution for infusion

PRODUCT USE:

Antineoplastic

MANUFACTURER:

Intas Pharmaceuticals Ltd.
Plot No. 457, 458
Village-Matoda,
Bavla Road, Ta. Sanand,
Dist. Ahmedabad-382 210,
Gujarat, India

MARKETING AUTHORISATION HOLDER:

Accord Healthcare Limited
Sage House
319, Pinner Road
North Harrow
Middlesex, HA1 4HF
United Kingdom

RECOMMENDED INTERNATIONAL NONPROPRIETARY NAME:

Docetaxel

CHEMICAL NAME:

(2R, 3S)-N-Carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5 beta, 20-epoxy-1, 2 alpha, 4, 7 beta, 10 beta, 13 alpha-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate

CHEMICAL FORMULA:

$C_{43}H_{53}NO_{14}$

CHEMICAL FAMILY:

Plant Alkaloids & other natural products (Taxanes)

HOW SUPPLIED:

- For 20 mg/1 ml: 5 ml clear glass (type I) vial with fluorotec plus rubber stopper and aluminium seals with orange flip-off cap.
- For 80 mg/4 ml: 5 ml clear glass (type I) vial with fluorotec plus rubber stopper and aluminium seals with red flip-off cap.
- For 160 mg/8 ml: 10 ml clear glass (type I) vial with fluorotec plus rubber stopper and aluminium seals with red flip-off cap.

SECTION 2 – HAZARDS IDENTIFICATION

POTENTIAL HEALTH HAZARDS
EYE:

Irritating to the eyes in the event of an inadvertent splash.

SKIN:

Not irritating to the skin but may be absorbed and made available systemically.



DOCETAXEL CONCENTRATE FOR SOLUTION FOR INFUSION

INGESTION:

Moderately toxic if inadvertently ingested.

INHALATION:

Compound is supplied in aqueous solution therefore this is not an expected route of exposure.

CHRONIC EFFECTS:

If the compound is bioavailable via the route of exposure and exposure occurs for prolonged periods of time, potential adverse effects include neurotoxicity, myelosuppression, leucopenia, necrosis of the intestinal epithelium, testicular atrophy and lymphoid organ depletion. The compound was negative in the Ames test but positive in other genotoxicity assays. The Guinea-Pig Anaphylaxis assay was negative

SECTION 3 – COMPOSITION/DATA ON COMPONENTS**ACTIVE INGREDIENT:**

Docetaxel

INACTIVE INGREDIENTS:

polysorbate 80, citric acid anhydrous (for pH adjustment), ethanol anhydrous.

SECTION 4 – EMERGENCY AND FIRST AID MEASURES**EYES:**

Immediately flush eyes with plenty of water for fifteen minutes. Seek medical attention.

SKIN:

Wash with copious amounts of soap and water. Seek medical attention.

INGESTION:

Seek medical attention. Induce only as directed by medical personnel. Never give anything by mouth to an unconscious person.

INHALATION:

If mist is inhaled, remove to fresh air and seek medical attention. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

NOTE TO PHYSICIANS:

Consult the Physicians' Desk Reference for additional details.

SECTION 5 – FIRE FIGHTING MEASURES**HAZARDOUS COMBUSTION PRODUCTS:**

CO, CO₂ and oxides of nitrogen may be generated in a fire.

EXTINGUISHING MEDIA:

Packaging material fires may be extinguished with water, carbon dioxide, or dry chemical.

FIREFIGHTING INSTRUCTIONS:

Firefighting in confined spaces requires full protective gear and supplied air respiratory protection.

FIRE / EXPLOSION HAZARDS:

Fine particles (such as dust and mists) may fuel fires/explosions.

SECTION 6 – ACCIDENTAL RELEASE MEASURES**SMALL SPILL:**

Don Solvex nitrile NBR gloves and eye protection. Absorb liquid.

LARGE SPILL:

Don Solvex nitrile NBR gloves, tyvek outer clothing and face protection. Absorb liquid.

SPILL WASTE DISPOSAL:

Spilled liquid can be destroyed by mixing with a caustic ethanol solution (30% ethanol/70% water/1N sodium hydroxide) with sufficient caustic added to raise the solution pH above 11, stirring at room temperature for 5 hours. Solution volume must be sufficient enough to prevent precipitation of docetaxel. The residual destruction products of docetaxel do not possess cytotoxic activity. The resultant solution can be disposed of as waste in accordance with all federal, state, and local regulations as specified in Section 13

SECTION 7 – HANDLING AND STORAGE**HANDLING:**

Protect package from damage.

STORAGE:

Do not store above 25°C. Store in the original package in order to protect from light.

SECTION 8 – PHYSICAL AND QUIMICAL PROPERTIES**DESCRIPTION:**

A clear pale yellow to brownish yellow viscous solution.

pH:

2.5 to 4.0.

PRESERVATIVE:

Docetaxel concentrate for infusion does not contain any preservative.

ANTIOXIDANTS:

No antioxidants have been included in this formulation.

SECTION 9 – EXPOSURE CONTROLS/PERSONAL PROTECTION**ENGINEERING CONTROLS:**

Operations should be designed to offer no significant exposure to the liquid.

RESPIRATORY PROTECTION:

Recommended to protect against ethanol vapor inhalation for manufacturing operations without local exhaust ventilation or when cleaning up a very large spill.

SKIN PROTECTION:

Solvex nitrile NBR gloves are recommended if potential exists for significant hand/wrist exposure. Latex gloves will offer temporary protection from small splashes but should be changed immediately if vomiting splash occurs.

EYE PROTECTION:

Safety glasses recommended. Full-face protection recommended for spill cleanup if potential exists for splashing.

SECTION 10 – STABILITY AND REACTIVITY**INCOMPATIBILITY:**

Direct light and heat.

HAZARDOUS DECOMPOSITION PRODUCTS:

No data

HAZARDOUS POLYMERIZATION:

Will not occur

SECTION 11 – TOXICOLOGY INFORMATION**DOCETAXEL:**

>2000 mg/kg p.o. rat LD50. Moderately toxic by ingestion. Sub-chronic animal bioassays indicate potential for neurotoxicity, myelosuppression, leucopenia, necrosis of the intestinal epithelium, testicular atrophy and lymphoid organ depletion. The compound was negative in the Ames test but positive in the in vitro and in vivo Micronucleus assay. The Guinea-pig Anaphylaxis assay was negative.

SECTION 12 – ECOLOGICAL INFORMATION

Based upon water solubility and Log P (octanol/water partition coefficient), the compound should partition to the aquatic compartment fairly exclusively.

SECTION 13 – DISPOSAL CONSIDERATIONS

Waste must be disposed of in accordance with all federal, state, and local regulations. Incineration is the preferred method.

SECTION 14 – TRANSPORTATION INFORMATION

No classification currently assigned.

SECTION 15 – REGULATORY INFORMATION

TSCA Status: No

CERCLA Section 103: No

SARA Section 302: No

SARA Section 304: No

SARA Section 313: No

SECTION 16 – OTHER INFORMATION

Report to the manufacturer any allegations of adverse effects related to handling or accidental contact with this material.

The information contained herein is based upon data considered true and accurate. However, no warranties express or implied, as to the adequacy of the information contained herein. This information is offered solely for the user's consideration, investigation, and verification.